Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

An update on molecular biology of thyroid cancers.

Author information

Affiliations

  • 1. Ege University, Faculty of Medicine, Department of Nuclear Medicine, 35100 Bornova, İzmir, Turkey.
      Authors
    • Omur O 1
    (1 author)
  • 2. İzmir Institute of Technology, Department of Molecular Biology and Genetics, 35430 Urla, İzmir, Turkey.
      Authors
    • Baran Y 2
    (1 author)

ORCIDs linked to this article

Critical Reviews in Oncology/hematology, 18 Dec 2013, 90(3):233-252
https://doi.org/10.1016/j.critrevonc.2013.12.007 PMID: 24405857 

Review

Abstract 

Differentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There are several histological variants such as papillary and follicular thyroid carcinoma. Many patients with well-differentiated subtypes of DTC are cured by surgery alone or with radioiodine, while poorly differentiated types usually have a worse prognosis. The aggressiveness of thyroid tumors is closely linked to specific gene alterations. Several diagnostic and prognostic molecular markers such as BRAF and RAS point mutations; RET/PTC and PAX8/PPARγ gene rearrangements; MAPK, PI3K, p53, Wnt-beta catenin, HIF1α and NF-kappaB signaling pathways; microRNA profiles and aberrant methylation have been demonstrated in more than 70% of DTC. Diagnostic use of these molecular markers may be optimized for identifying higher risks of mortality, tumor recurrence and metastatic potential. Understanding the molecular biology of thyroid cancers can be an important avenue for diagnosis and treatment of radioiodine-refractory or inoperable DTC patients with novel molecular targeted therapeutic agents.

Full text links 

Read article at publisher's site: https://doi.org/10.1016/j.critrevonc.2013.12.007

Read article for free, from open access legal sources, via Unpaywall: https://gcris.iyte.edu.tr/bitstream/11147/5405/1/5405.pdfUnpaywall

References 

Articles referenced by this article (287)

Show 10 more references (10 of 287)

Citations & impact 

Impact metrics

52
Citations
Jump to Citations
1
Data citation
Jump to Data

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/2283233
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/2283233

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1016/j.critrevonc.2013.12.007

Supporting
Mentioning
Contrasting
3
82
1

Article citations

Go to all (52) article citations

Data 

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.